JQAD1|CAS 2417097-18-6|DC Chemicals

Cas No.:	2417097-18-6
Chemical Name:	JQAD1
Synonyms:	JQAD1
SMILES:	O=C1N(C(=O)O[C@]21CCC1=CC(NC(=O)CCCCCCCCCCCNC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)C(=O)C4=C3)=CC=C21)CC(=O)N([C@@H](C)C(F)(F)F)CC1C=CC(F)=CC=1
Formula:	C₄₈H₅₂F₄N₆O₉
M.Wt:	932.954906463623
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
In Vivo:	JQAD1 (40 mg/kg; i.p.; once daily, for 21 days) inhibits tumor growth in NSG mice with Kelly NB cell xenografts [1]. It also prolongs survival in these mice. In another study using CD1 mice, JQAD1 was administered at a dosage of 10 mg/kg via intraperitoneal injection for pharmacokinetic analysis [1]. The results showed that JQAD1 had a half-life of 13.3 hours (±3.37 SD) in murine serum and reached a maximum concentration (Cmax) of 7 μmol/L.
In Vitro:	JQAD1 inhibits the expression of EP300, suppresses H3K27ac modification, and induces apoptosis in Kelly NB cells (control group) rather than CRBN knockout cells [1]. Treatment with JQAD1 (0.5 or 1 μM; 6-96 hours) leads to early time-dependent induction of the sub G1 peak, indicating apoptosis in Kelly and NGP cells [1]. JQAD1 (1 μM; 12-36 hours) induces apoptosis in Kelly NB cells [1]. Cells treated with JQAD1 (0.5 μM; 24 hours) show upregulation of pro-apoptotic BH3 effectors BIM, BID, and PUMA, as well as pro-apoptotic mediators BAX, along with the upregulation of their inhibitors BCL2 and MCL1 [1]. JQAD1 (0.5 and 1 μM; 24 hours) disrupts MYCN expression [1]. JQAD1 (0.5 μM; 24 hours) results in loss of H3K27ac on chromatin [1]. JQAD1 (1.2 nM - 20 μM; 5 days) exhibits broad CRBN-dependent anti-tumor activity across cancer cell lines [1]. JQAD1 induces time-dependent degradation of EP300, observed as early as 16 hours [1]. Western Blot Analysis [1]: Cell Line: MYCN-amplified neuroblastoma (NB) cells Concentration: 0.1, 0.5, 1, 3, 5, and 10 µM Incubation Time: 24 hours Result: Demonstrated a dose-dependent decrease in EP300 expression, accompanied by a parallel loss of the H3K27ac modification. Induced selective loss of EP300 expression coincided with cleavage of PARP1, indicating the initiation of apoptosis. Western Blot Analysis [1]: Cell Line: Kelly NB cells Concentration: 1 µM Incubation Time: 12, 24, and 36 hours Result: Increased expression of cleaved caspase-3 and cleaved PARP1 in a dose-dependent manner.
References:	[1]. Durbin AD, et, al. EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discov. 2022 Mar 1;12(3):730-751.

Cat. No.	Product name	Field of application
DC65211	KT-474	KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.
DC39826	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1, is a cereblon degrader.
DC74523	XY-07-35	XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74496	HJM-561	HJM-561 is a potent, selective and orally bioavailable EGFR PROTAC degrader, selectively degrades the EGFR C797S-containing triple mutants Del19/T790M/C797S and L858R/T790M/C797S with DC50 values of 9.2 nM and 5.8 nM, respectively.
DC74494	GNE-0011	GNE-0011 is a monovalent, JQ1-based BRD4 degrader that is not linked to an E3 ligase binder, triggers proteasomal and ubiquitin-dependent selective degradation of BRD4 over BRD2 and BRD3.
DC74479	BSJ-05-037	BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78.
DC72756	JQAD1	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC50038	PROTAC SGK3 degrader-1	PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent SKG3 degrader based on PROTAC. PROTAC SGK3 degrader-1 (0.3 μM) induces 50% degradation of endogenous SGK3 within 2 hours, with maximal 80% degradation observed within 8 hours, accompanied by a loss of phosphorylation of NDRG1 (an SGK3 substrate).
DC48434	TD-165	TD165(TD 165) is a PROTAC-based cereblon (CRBN) degrader that degrads Cav1.2α with the DC50 of 20.4 nM, comprising a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
DC46405	ARD-2128	ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.